It’s Time To Pass a State False Claims Act in PA The Commonwealth of Pennsylvania continues to miss numerous golden opportunities to collect millions of dollars in taxpayer monies from individuals and corporations who defraud the Commonwealth. In order to rectify the situation the legislature needs to enact a State False Claims Act. The Act,...
U.S. District Court for the District of Massachusetts Refuses to Adopt Narrow Definition of SEC Whistleblower Under Dodd-Frank On October 16, 2013, a federal court in Massachusetts issued a ruling widely applauded by whistleblower attorneys and advocates. See Ellington v. Giacoumakis, No. 13-11791-RGS, 2013 WL 5631046 (D. Mass. Oct. 16, 2013). The primary issue in the decision...
UK Contemplates Qui Tam Provision It has recently been reported that the British government is contemplating the creation of a reward system, with qui tam provisions similar to the False Claims Act, to encourage whistleblowers to come forward with necessary information to root out government fraud and other white-collar crime. The U.K. Home Office, acting in concert with other...
$14 Million Award Signals SEC Is Embracing Its Whistleblower Program On October 1, 2013, the Securities and Exchange Commission (“SEC”) announced the payment of a $14,000,000 award to an, as yet, anonymous whistleblower, whose information led to the recovery of significant funds. The award, the largest to date issued by the SEC, is a significant...
8th Circuit Court of Appeals Greenlights Former Bayer Employee Qui Tam Whistleblower Suit On October 15, 2013, the United States Court of Appeals for the Eighth Circuit green-lighted a whistleblower lawsuit brought by a former Bayer employee, alleging that the company deceptively marketed its Baycol cholesterol drug. See U.S. ex rel. Laurie Simpson v. Bayer Healthcare,...
Financial Professionals Win Big in Appeals Court Ruling The Association for Financial Professionals features Eric L. Young and James McEldrew analysis of the Third Circuit Court of Appeals ruling that historic Sarbanes Oxley legislation empowers financial professionals to assert their professional ethics and standards questioning the legality of bills and invoices on the “reasonable belief”...
United States Joins Whistleblower Lawsuit Against Novartis Pharmaceuticals Philadelphia, Pa, April 26, 2013 PRWeb, Young Law Group (young-lawgroup.com; e-mail: eyoung@young-lawgroup.com) The United States Department of Justice has announced that it is intervening in a qui tam whistleblower suit under the False Claims Act accusing Novartis Pharmaceuticals Corporation of fraudulently billing Medicare, Medicaid, TRICARE, and other federal and state-funded...
Pharmaceutical Fraud – Do Your Part to Help Fight Unfortunately, too many pharmaceutical companies place the pursuit of profits above compliance with the law and the well-being of the innocent patients, who place their trust in their products. In order to protect their bottom line, some pharmaceutical companies perpetrate countless fraudulent schemes every year and...
IRS Whistleblower Program Proposed Changes Young Law Group Submits Public Comments to Dept. of Treasury on Proposed Changes to IRS Whistleblower Program Recognizing the potential threat to its current and future clients, as well as, the whistleblower advocacy community at large, Young Law Group today submitted official comments in response to proposed changes to the IRS Whistleblower...
False Claims Act The False Claims Act (“FCA”) is a federal statute that enables individuals (commonly referred to as “Relators”) to file lawsuits on the federal government’s behalf when the government has been defrauded. Nearly thirty States now have their own False Claims Act, many of which mirror the provisions of the federal False Claims Act. Lawsuits...